AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. QNCX
  4. [Form 4] Quince Therapeutics, Inc. Insider Trading Activity

[Form 4] Quince Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quince Therapeutics (NASDAQ:QNCX) filed a Form 4 on June 28 2025 reporting that President Charles S. Ryan executed an insider purchase on June 18 2025.

Ryan bought 7,548 common shares at $1.20 each and simultaneously acquired 7,548 warrants with the same $1.20 exercise price, expiring 06/18/2030. His direct ownership rose to 130,009 common shares, an increase of roughly 5.8 %. No other material transactions or disclosures were included in the filing.

Quince Therapeutics (NASDAQ:QNCX) ha presentato un modulo Form 4 il 28 giugno 2025, segnalando che il Presidente Charles S. Ryan ha effettuato un acquisto interno il 18 giugno 2025.

Ryan ha acquistato 7.548 azioni ordinarie al prezzo di $1,20 ciascuna e ha contemporaneamente acquisito 7.548 warrant con lo stesso prezzo di esercizio di $1,20, con scadenza il 18/06/2030. La sua partecipazione diretta 猫 salita a 130.009 azioni ordinarie, un aumento di circa il 5,8%. Nel deposito non sono state incluse altre transazioni o comunicazioni rilevanti.

Quince Therapeutics (NASDAQ:QNCX) present贸 un Formulario 4 el 28 de junio de 2025 informando que el Presidente Charles S. Ryan realiz贸 una compra interna el 18 de junio de 2025.

Ryan compr贸 7,548 acciones comunes a $1.20 cada una y simult谩neamente adquiri贸 7,548 warrants con el mismo precio de ejercicio de $1.20, que vencen el 18/06/2030. Su propiedad directa aument贸 a 130,009 acciones comunes, un incremento de aproximadamente el 5.8%. No se incluyeron otras transacciones o divulgaciones relevantes en la presentaci贸n.

Quince Therapeutics (NASDAQ:QNCX)電� 2025雲� 6鞗� 28鞚� Form 4毳� 鞝滌稖頃橃棳 靷灔 Charles S. Ryan鞚� 2025雲� 6鞗� 18鞚� 雮措秬鞛� 毵れ垬毳� 鞁ろ枆頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟.

搁测补苍鞚赌 7,548欤� 氤错喌欤�毳� 欤茧嫻 $1.20鞐� 毵れ垬頄堨溂氅� 霃欖嫓鞐� 霃欖澕頃� 頄夓偓臧�瓴� $1.20, 毵岅赴鞚� 2030雲� 6鞗� 18鞚检澑 7,548 鞗岆煱韸�霃� 旆摑頄堨姷雼堧嫟. 攴胳潣 歆侅爲 靻岇湢 欤检嫕 靾橂姅 鞎� 5.8% 歃濌皜顷� 130,009欤� 氤错喌欤�搿� 電橃柎雮姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 雼るジ 欷戩殧頃� 瓯半灅雮� 瓿奠嫓電� 韽暔霅橃 鞎婌晿鞀惦媹雼�.

Quince Therapeutics (NASDAQ:QNCX) a d茅pos茅 un formulaire 4 le 28 juin 2025, indiquant que le pr茅sident Charles S. Ryan a effectu茅 un achat d鈥檌niti茅 le 18 juin 2025.

Ryan a achet茅 7 548 actions ordinaires au prix de 1,20 $ chacune et a simultan茅ment acquis 7 548 bons de souscription avec le m锚me prix d鈥檈xercice de 1,20 $, expirant le 18/06/2030. Sa d茅tention directe est mont茅e 脿 130 009 actions ordinaires, soit une augmentation d鈥檈nviron 5,8 %. Aucun autre mouvement ou divulgation significative n鈥檃 茅t茅 inclus dans le d茅p么t.

Quince Therapeutics (NASDAQ:QNCX) reichte am 28. Juni 2025 ein Formular 4 ein und berichtete, dass Pr盲sident Charles S. Ryan am 18. Juni 2025 einen Insider-Kauf get盲tigt hat.

Ryan kaufte 7.548 Stammaktien zu je 1,20 $ und erwarb gleichzeitig 7.548 Warrants mit demselben Aus眉bungspreis von 1,20 $, die am 18.06.2030 verfallen. Sein Direktbesitz stieg auf 130.009 Stammaktien, eine Steigerung von etwa 5,8 %. Weitere wesentliche Transaktionen oder Offenlegungen wurden in der Einreichung nicht angegeben.

Positive
  • None.
Negative
  • None.

Quince Therapeutics (NASDAQ:QNCX) ha presentato un modulo Form 4 il 28 giugno 2025, segnalando che il Presidente Charles S. Ryan ha effettuato un acquisto interno il 18 giugno 2025.

Ryan ha acquistato 7.548 azioni ordinarie al prezzo di $1,20 ciascuna e ha contemporaneamente acquisito 7.548 warrant con lo stesso prezzo di esercizio di $1,20, con scadenza il 18/06/2030. La sua partecipazione diretta 猫 salita a 130.009 azioni ordinarie, un aumento di circa il 5,8%. Nel deposito non sono state incluse altre transazioni o comunicazioni rilevanti.

Quince Therapeutics (NASDAQ:QNCX) present贸 un Formulario 4 el 28 de junio de 2025 informando que el Presidente Charles S. Ryan realiz贸 una compra interna el 18 de junio de 2025.

Ryan compr贸 7,548 acciones comunes a $1.20 cada una y simult谩neamente adquiri贸 7,548 warrants con el mismo precio de ejercicio de $1.20, que vencen el 18/06/2030. Su propiedad directa aument贸 a 130,009 acciones comunes, un incremento de aproximadamente el 5.8%. No se incluyeron otras transacciones o divulgaciones relevantes en la presentaci贸n.

Quince Therapeutics (NASDAQ:QNCX)電� 2025雲� 6鞗� 28鞚� Form 4毳� 鞝滌稖頃橃棳 靷灔 Charles S. Ryan鞚� 2025雲� 6鞗� 18鞚� 雮措秬鞛� 毵れ垬毳� 鞁ろ枆頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟.

搁测补苍鞚赌 7,548欤� 氤错喌欤�毳� 欤茧嫻 $1.20鞐� 毵れ垬頄堨溂氅� 霃欖嫓鞐� 霃欖澕頃� 頄夓偓臧�瓴� $1.20, 毵岅赴鞚� 2030雲� 6鞗� 18鞚检澑 7,548 鞗岆煱韸�霃� 旆摑頄堨姷雼堧嫟. 攴胳潣 歆侅爲 靻岇湢 欤检嫕 靾橂姅 鞎� 5.8% 歃濌皜顷� 130,009欤� 氤错喌欤�搿� 電橃柎雮姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 雼るジ 欷戩殧頃� 瓯半灅雮� 瓿奠嫓電� 韽暔霅橃 鞎婌晿鞀惦媹雼�.

Quince Therapeutics (NASDAQ:QNCX) a d茅pos茅 un formulaire 4 le 28 juin 2025, indiquant que le pr茅sident Charles S. Ryan a effectu茅 un achat d鈥檌niti茅 le 18 juin 2025.

Ryan a achet茅 7 548 actions ordinaires au prix de 1,20 $ chacune et a simultan茅ment acquis 7 548 bons de souscription avec le m锚me prix d鈥檈xercice de 1,20 $, expirant le 18/06/2030. Sa d茅tention directe est mont茅e 脿 130 009 actions ordinaires, soit une augmentation d鈥檈nviron 5,8 %. Aucun autre mouvement ou divulgation significative n鈥檃 茅t茅 inclus dans le d茅p么t.

Quince Therapeutics (NASDAQ:QNCX) reichte am 28. Juni 2025 ein Formular 4 ein und berichtete, dass Pr盲sident Charles S. Ryan am 18. Juni 2025 einen Insider-Kauf get盲tigt hat.

Ryan kaufte 7.548 Stammaktien zu je 1,20 $ und erwarb gleichzeitig 7.548 Warrants mit demselben Aus眉bungspreis von 1,20 $, die am 18.06.2030 verfallen. Sein Direktbesitz stieg auf 130.009 Stammaktien, eine Steigerung von etwa 5,8 %. Weitere wesentliche Transaktionen oder Offenlegungen wurden in der Einreichung nicht angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ryan Charles S.
(Last) (First) (Middle)
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD., SUITE 273
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/18/2025 A 7,548 A $1.2 130,009 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $1.2 06/18/2025 A 7,548 06/18/2025 06/18/2030 Common Shares 7,548 $0.125 7,548 D
Explanation of Responses:
/s/ Charles S. Ryan 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many QNCX shares did the president buy in the June 2025 Form 4 filing?

The filing shows President Charles S. Ryan acquired 7,548 common shares on 06/18/2025 at $1.20 per share.

What is Charles S. Ryan's total direct ownership after the transaction?

According to the Form 4, he now beneficially owns 130,009 common shares of Quince Therapeutics.

Did the insider acquire any derivative securities?

Yes. He obtained 7,548 warrants exercisable at $1.20 and expiring on 06/18/2030.
Stock QNCX logo
Quince

NASDAQ:QNCX

QNCX Rankings

#7367 Ranked by Market Cap
N/A Ranked by Dividends

QNCX Latest News

Jul 10, 2025
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
Jun 25, 2025
Quince Therapeutics to Participate at A-T Society鈥檚 2025 A-T Clinical Research Conference
Jun 18, 2025
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
Jun 12, 2025
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Jun 3, 2025
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

QNCX Latest SEC Filings

Jul 1, 2025
[D] Quince Therapeutics, Inc. SEC Filing
Jun 23, 2025
[Form 4] Quince Therapeutics, Inc. Insider Trading Activity
Jun 23, 2025
[Form 4] Quince Therapeutics, Inc. Insider Trading Activity

QNCX Stock Data

83.43M
39.50M
13.52%
23.46%
5.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO